Furthermore, large-scale analysis of public -omics data has identified ALDH1A1 as a potential therapeutic target, providing a multitarget treatment strategy for future clinical research on NAFLD (Ma et al., 2021). The gene discussed is ALDH1A1; the disease is metabolic dysfunction-associated steatotic liver disease.